Jason Helfstein, Oppenheimer head of internet research, joins 'The Exchange' to discuss Spotify as the stock sinks on Q2 ...

Oppenheimer Asset Management on Monday raised its year-end target for the S&P 500 index to 7,100, the highest among major ...

Trump's trade deals with the EU and Japan pave the way for the stock market to end with it's third straight annual gain of ...

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Analysts upgraded Carvana shares, arguing the company is a "digitally-driven disruptor" in the fractured used car market.

Jensen Huang believes questions of whether artificial intelligence (AI) could destroy humanity are fear-mongering — and get ...

Carvana (NYSE:CVNA) tracked higher on Friday after Oppenheimer boosted its rating on the auto retailer to Outperform after ...

Oppenheimer initiated coverage of the buy now, pay later firm Monday, issuing an "outperform" rating for Affirm stock.

Christopher Nolan’s Oppenheimer resurfaces on global streaming charts two years after release, trending in over 40 countries.

Oppenheimer analyst Brian Nagel sees upside in Carvana stock to $450. CVNA is set to report its fiscal second-quarter ...

There are many hugely impressive things about the film – not least the central, Oscar-winning, performance from Cillian ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.